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A new series of 6-substituted 2-aminobenzothiazole derivatives were synthesized and screened in vitro
as potential antimicrobials. Almost all the compounds showed antifungal activity. In particular, com-
pounds 1n,o, designed on the basis of molecular modeling studies, were the best of the series, showing
MIC values of 4e8 mg/mL against Candida albicans, Candida parapsilosis and Candida tropicalis. None of
the two compounds did show any cytotoxicity effect on human THP-1 cells.
 2013 Elsevier Masson SAS. All rights reserved.1. Introduction
One of the major problems we are facing today in the context of
infectious diseases is the relentless increase and spread of antimi-
crobial resistance. Thus, studies for the identification of novel tar-
gets and drugs for the treatment of infectious diseases are at the
forefront. In this perspective, for example, we recently determined
the X-ray crystallographic structure of Enterococcus faecalis thy-
midylate synthase, which should be a potential target for antibac-
terial therapy [1]. Many heterocyclic nuclei, such as 1,3,4-
thiadiazole, benzimidazole, 1,3,5-triazine, and benzothiazole have
been recently reviewed as antimicrobial agents [2,3]. Our attention
was focused to the benzothiazole nucleus [4]. In fact, benzothiazole
derivatives possess a wide spectrum of biological applications such
as antitumor, schictosomicidal, anti-inflammatory, anticonvulsant,
antidiabetic, antipsychotic, diuretic, and antimicrobial activities [5].
In the past, our research group was interested in the synthesis and
microbiological screening of a series of 2-mercapto-1,3-
benzothiazole derivatives, some of which showed antibacterial
activity against Gram-positive and negative bacterial strains [6].
Results showed that the SH moiety at the 2 position of the: þ39 080 5442724.
).
son SAS. All rights reserved.heterocyclic nucleus led to a remarkable antibacterial activity. In a
search for new leads toward potent antimicrobial agents, given the
isosteric relationship existing between SH and NH2 groups,
following a previous work [7], we synthesized a series of 2-amino-
1,3-benzothiazoles (Fig. 1) and tested their in vitro antimicrobial
activity. It was reported, indeed, that several 2-aminobenzothiazole
derivatives, variously substituted, showed antifungal activity, even
though much lower than those of the reference antifungal agent
used [8]. In particular, as it was already done for the series of 2-
mercapto-1,3-benzothiazole derivatives [6], substitutions at posi-
tion 6 of the aryl moiety was investigated. QSAR and docking
studies gave valuable hints assessing lipophilicity and steric hin-
drance as main molecular determinants most likely affecting the
newly synthesized benzothiazole derivatives in their antifungal
activity.2. Results and discussion
2.1. Chemistry
Compounds 1a and 1jem were commercially available. Com-
pounds 1bei,n,o (Table 1) were synthesized as depicted in Scheme
1. Alkyl and aryl alcohols 2eeh,n were reacted with 4-nitrophenol
under Mitsunobu conditions [9e12] to give their nitro derivatives
NS
NH2
R
R = H, Alk, OAlk, OAr
Fig. 1. Structures of 2-amino-1,3-benzothiazole derivatives (1aeo).
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anilines 6eeh,n. Anilines 6bed,o were commercially available.
Aniline 6i was obtained by reducing nitro derivative 4 to aniline 5
and then by submitting the latter to a Mitsunobu reaction with
phenol. 2-Aminobenzothiazole derivatives 1bei,n,owere prepared
via thiocyanation of 6eei,n,o [13]. In this reaction ammonium
thiocyanate and bromine were used to generate thiocyanogen in
situ [14].2.2. Antimicrobial studies
2.2.1. Antibacterial studies
According to the Clinical Laboratory Standards Institute (CLSI)
guidelines [15] compounds 1aeo (Table 1) were tested against
Gram-positive and Gram-negative bacteria belonging to the ATCC
collection (Staphylococcus aureus 29213, E. faecalis 29212, Escher-
ichia coli 25922) using Norfloxacin (NRF) as reference drug. The
results, expressed as MIC (mg/mL), are listed in Table 2. The anti-
bacterial screening revealed that the compounds showed very low
to no activity against all the bacterial strains tested, thus underlying
that isosteric substitution SH/NH2 brought to a loss of the anti-
bacterial activity, as evidenced by comparing 1b,c,jel with their
corresponding isosters previously reported [6].
2.2.2. Antifungal studies
Compounds 1aeo (Table 1) were screened, according to CLSI
guidelines [16], against a panel of fungi strains (Candida albicans
10231, Candida parapsilosis 22019, Candida tropicalis 750, Candida
krusei 6258) belonging to the ATCC collection. Fluconazole was
used as reference drug. The results, expressed as MIC (mg/mL), are
listed in Table 3. All the 6-substituted 2-amino-1,3-mercapto
benzothiazole derivatives show slight to high antifungal activity
against all the Candida spp. tested, while unsubstituted 1a was
inactive. The electron-withdrawing effect at the 6-position of theTable 1
Structures of compounds 1aeo.
N
S
NH2
R
Compd R
1a H
1b MeeO
1c EteO
1d PheO
1e BneO
1f Ph(CH2)2eO
1g Ph(CH2)3eO
1h Ph(CH2)4eO
1i PhOCH2
1j F
1k Cl
1l CF3
1m CF3O
1n 4-CleBneO
1o 4-ClePheObenzothiazole moiety of halogens, such as a chlorine and fluorine
atom (1j,k, Fig. 2) and a trifluoromethyl group (1l, Fig. 2) was first
investigated. These three compounds were slightly active against
all Candida spp. tested. In particular,1lwas the most active of them,
especially against C. albicans. Then, we introduced an alkoxy or
aryloxy moiety (1beh) in the same position. Results showed that
antifungal activity enhanced with the increase of steric hindrance
at position 6 of the heterocycle. In fact, compounds 1b and 1cwere
slightly active while phenoxy and benzyloxy derivatives (1d and 1e,
respectively) were much more potent. Compound 1d was equi-
potent to 1c against C. albicans but was much more active against
C. parapsilosis, C. tropicalis and C. krusei (MIC values: 16, 32, 32 vs
128, 128, 256 mg/mL, respectively). The benzyloxy derivative 1ewas
more active than the others against C. albicans and showed high
activity also against C. parapsilosis and C. tropicalis. Thus, we
investigated a possible homologation of the alkyl chain with one to
three methylene moieties obtaining compounds 1f, 1g and 1h,
respectively. They were generally less active than compound 1e
evidencing that elongation of the alkyl chain was detrimental for
activity. In particular, compound 1h was nearly inactive against
fungi. Compound 1iwas less active than its position isomer 1e. This
finding suggests that conceivably moving the oxygen atom is
detrimental for activity. Among the series of alkoxy derivatives, we
also tested the well-known drug riluzole (1m), the only FDA-
approved drug to treat amyotrophic lateral sclerosis [17]. It was
just slightly active against all the species of Candida. Finally, com-
pounds 1n,o, suggested by modeling studies (see below), were
indeed the most active of the series against C. albicans, C. para-
psilosis and C. tropicalis. It is noteworthy that compound 1n was
even as potent as the reference on C. tropicalis.
2.3. Molecular modeling studies
A molecular modeling study was carried out to better perceive
and evaluate the biological profile within the series under study.
In the first step we make use of classical 2D-QSAR to gain a sound
regression model, showing the dependence of the antifungal ac-
tivity on lipophilicity. In particular, as proposed by Hansch [18],
pMIC data showed parabolic dependence by hydrophobic che-
motype of benzothiazoles, as scored by the CLogP values (Fig. 2,
Table 4). It has to be pointed out that model comprising com-
pounds 1bem was indeed statistically significant (r2 ¼ 0.624), but
a valuable increase of the explained variance (r2 ¼ 0.750) was
achieved excluding from the regression model 1d, the lone de-
rivative bearing the phenyl ring directly branched to the oxygen at
position 6 of the aryl moiety. Afterward, the antifungal activity
was interpreted through docking experiments. Lanosterol 14a-
demethylase (CYP51) is a member of the cytochrome P450 su-
perfamily, which catalyzes the oxidative removal of the 14a-
methyl group of lanosterol to give D14,15-desaturated in-
termediates in ergosterol biosynthesis [19]. The development of
inhibitors of CYP51 in fungi has provided a rich source of drugs,
such as clotrimazole, ketoconazole, fluconazole, and itraconazole
[20], responsible for the cell growth inhibition due to ergosterol
depletion. The same cytochrome is also targeted by drugs (i.e.
benzothiazines and benzoxazines) [20e22] characterized by a
molecular scaffold similar to the benzothiazoles here presented.
Moreover, the importance of CYP51 as a plausible target in the
treatment of C. albicans infections has been already and success-
fully reported [23e25]. On the basis of this evidence, compounds
1bei were therefore docked into the catalytic site of the homology
based model of C. albicans CYP51 (CA-CYP51) [26,27] which has
already been successfully used in a previous study on antifungal
agents [7]. Docking binding poses highlighted some interesting
features that might be in charge of the antifungal activity of the
Scheme 1. Reagents and conditions: (i) 4-nitrophenol (for compounds 3eeh,n) or phenol (for compound 6i), PPh3, DIAD, anhyd THF, rt; (ii) HCOONH4, 10% Pd/C, i-Pr2O/H2O/THF, rt
(for compounds 6feh); H2, 10% Pd/C, MeOH/abs EtOH, rt (for compounds 5 and 6e), H2, 10% Pd/C, abs EtOH, rt (for compounds 6n,o); (iii) Br2, NH4SCN, HCOOH/CH3COOH, 0 C then
rt.
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accommodate the active site mainly anchoring the heterocyclic
system nearly perpendicular to the heme group of CA-CYP51, by
mean of a coordination bond involving the iron and the nitrogen
atoms, as it might be perceived from the docking of the most
potent antifungal agent 1e depicted in Fig. 3. As a figure of merit,
the same binding topology has also been experimentally observed
in the X-ray structures of other thiazoles in complex with cyto-
chrome different from the CA-CYP51, but functionally related to
our target [28]. At the same time, the amino group at position 2
reinforces the binding engaging Thr311 and Gly307 with
hydrogen-bonding mediated polar interactions. This evidence
then facilitates the positioning of the apolar and steric hindered
substituents into a most likely hydrophobic dome placed above
the heme group. It is very interesting to note that the benzyl
moiety of the most potent antifungal agent 1e make extensive pe
p stackings with Phe228 and Tyr118. Other remarkable indications
have to be ascribed to the reduced accessible surface of the active
site lodge, shaped and delimited by bulky residues, namely
Met508 and Val509. This evidence might justify, at least in part,
the very low pMIC of derivatives bearing very large and long
lipophilic groups hampering a proper docking (i.e. 1h). On the
other hand, compounds with a very small group, and lacking the
phenyl ring (i.e. 1b,c), might not be capable to establish significant
interactions, resulting then with a lower antifungal potency. It may
be noted that the need of a suitable functional group, in terms ofTable 2
Antibacterial activity results of 2-aminobenzothiazole derivatives 1aeo (MIC, mg/
mL).
Microorganism (MIC, mg/mL)
Gram-positive Gram-negative
S.a. 29213 E.f. 29212 E.c. 25922
1a >512 >512 >512
1b 128 128 >512
1c 512 512 >512
1d >512 >512 >512
1e >512 >512 >512
1f >512 128 >512
1g 512 128 >512
1h 512 256 >512
1i 256 128 >512
1j >512 >512 >512
1k >512 >512 >512
1l 256 256 >512
1m 256 512 512
1n 256 256 >512
1o 512 512 >512
NRF 0.5 4 0.03
Antibacterial activity was estimated by using CLSI assay [15]. Abbreviations: S.a.:
S. aureus; E.f.: E. faecalis; E.c.: E. coli; NRF: norfloxacin.bulkiness and/or lipophilicity, was already highlighted in the 2D-
QSAR study previously mentioned. As long as this evidence was
concerned, the synthesis of novel compounds was perceived and
carried out according to the insights achieved by the modeling
study. Indeed 2D-QSAR highlighted the affect of lipophilicity on
antifungal activity, suggesting thereafter that an increase of this
chemical cliché would have been at least mandatory to challenge
the pMIC data. Moreover, the nature of the CA-CYP51 binding cleft
was proved from dockings to be most likely characterized by ar-
omatic, or at least very low polar, residues. This guided us in the
design of 1n,o as antifungals with improved activity. As expected
these analogs were found to be the most potent of the series. The
better antimicrobial profile might be ascribed not merely to a
balancing in lipophilicity, but also to the additional and favorable
van der Waals interactions occurring between the chlorine atom
and the side chain of Val509 (see Fig. 3).2.4. Cytotoxicity assay
The most active compounds of the series (1n,o) were tested for
their cytotoxicity by the measurement of the release of the cytosolic
enzyme lactate dehydrogenase (LDH) and by the uptake of trypan
blue in damaged cells. The results obtained on human THP-1 cells
indicate that these compounds shownocytotoxicity. Fig. 4 shows that
1n caused a significant increase for both markers for concentrations
20 mg/mL (4MIC) and that 1o did not cause any LDH release and
induced a small but significant increase in the number of trypanblue-
stained cells when its concentration was 40 mg/mL (10MIC).Table 3
Antifungal activity results of 2-aminobenzothiazole derivatives 1aeo (MIC, mg/mL).
Microorganism (MIC, mg/mL)
C.a. 10231 C.p. 22019 C.t. 750 C.k. 6258
1a >512 >512 >512 >512
1b 256 256 256 512
1c 128 128 128 256
1d 128 16 32 32
1e 8 8 8 64
1f 8 16 32 16
1g 32 16 16 16
1h 512 128 512 >512
1i 32 16 16 64
1j 256 128 256 256
1k 64 64 64 128
1l 16 64 64 64
1m 64 64 128 128
1n 4 8 4 64
1o 8 4 8 32
FCN 2 2 4 32
Antifungal activity was estimated by using CLSI assay [16]. Abbreviations: C.a.:
C. albicans; C.p.: C. parapsilosis; C.t.: C. tropicalis; C.k.: C. krusei; FCN: fluconazole.
Fig. 2. Plot of pMIC vs CLogP data. Data not included in the regression model are
represented by square. Fig. 3. Docking poses for 1e (left) and 1n (right) in the active site of CA-CYP51. Ligands
and iron atom are displayed as ball and stick to help interpretation.
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A new series of 2-amino-1,3-benzothiazole derivatives were
synthesized, characterized by mass, 1H NMR and IR spectra, and C,
H, N, analyses. Comparison of these compounds with the series of
2-mercapto-1,3-benzothiazole derivatives previously reported [6]
showed that the isosteric substitution SH/NH2 at position 2
brought to the loss of activity against bacteria but to the appearance
of an interesting activity toward fungi strains. This result confirms
our previous hypothesis that the SH moiety at the 2 position of the
heterocyclic nucleus is crucial for antibacterial activity. In this work,
substitutions at the 6-position of the heterocyclic moiety were
investigated. All the newly synthesized compounds (1bei,n,o),
together with commercial 1a,jem, were investigated for their
in vitro antimicrobial activities. Among the screened samples, no
compound showed interesting antibacterial activity, as expected.
On the contrary, most of the compounds were interesting for their
antifungal activity. In particular, compound 1n showed the highest
antifungal activity against C. albicans (MIC: 4 mg/mL), followed by
compounds 1e,f,o (MIC: 8 mg/mL). Compound 1n was also very
active against C. tropicalis, showing the same MIC value as the
reference (4 mg/mL), followed by compounds 1n,o (MIC: 8 mg/mL).
Compound 1owas the best of the series against C. parapsilosis (MIC:
4 mg/mL) followed by compounds 1e,n (MIC: 8 mg/mL). It is worthy
of note that both compounds 1f and 1gwere indeed two-fold moreTable 4
Lipohilicity, binding energy and antifungal activity of derivatives 1beo.
pMICa CLogPb FEB (kcal/mol)c Rankd Populatione
1b 2.85 1.81 5.00 1 68
1c 3.18 2.34 5.07 4 2
1d 3.28 3.88 6.64 1 129
1e 4.51 3.46 6.95 1 13
1f 4.53 3.69 6.67 2 12
1g 3.95 4.37 7.07 2 15
1h 2.77 4.85 ndf e e
1i 3.90 3.46 7.16 1 53
1j 2.82 1.94 4.87 1 88
1k 3.46 2.49 5.42 1 171
1l 4.13 2.46 5.08 1 110
1m 3.56 2.84 4.59 2 31
1n 4.86 4.06 6.49 1 70
1o 4.54 4.48 6.19 5 3
a Expressed as Log ¼ 1/MIC.
b Calculated using Advanced Chemistry Development (ACD) Software.
c Free Energy of Binding.
d Pose rank according to the FEB scoring.
e Number of similar docked conformations found in the same cluster.
f No docking poses (see text).potent than the reference compound fluconazole against C. krusei.
In conclusion, the presence of the substitution at position 2 of the
heterocyclic moiety is crucial for benzothiazole derivatives activity:
in particular, 2-mercapto derivatives were generally more active
against bacteria, while the 2-amino ones were more potent against
fungi. Moreover, as also suggested by the molecular modeling
studies, data suggests the importance of the substitution with
bulky groups at the 6-position of the 2-aminobenzothiazole moiety
for enhancing antifungal activity, being the 6-benzyloxy derivative
1e the best of the series against most of the fungal strains used.
Homologation of the alkyl chain brought to a reduction of anti-
fungal activity, except for C. krusei, against which the most active of
the series were compounds 1f and 1g. The best compounds of the
series, 1n,o, were also screened for their cytotoxicity and did not
show any toxic effects for human THP-1 cells when concentrations
are maintained below 4 (1n) or 10 (1o) their MIC. The current
study therefore suggests that 2-amino-1,3-benzothiazoles 1n,o are
promising scaffolds for the development of novel antifungal agents
against Candida spp.4. Experimental
4.1. Chemistry
Chemicals were purchased from SigmaeAldrich or Lancaster.
Yields refer to purified products and were not optimized. The
structures of the compounds were confirmed by routine spectro-
metric and spectroscopic analyses. Only spectra for compounds not
previously described are given. Alcohols 2eeh,n and 4 and anilines
6bed,o were commercially available. Melting points were deter-
mined on a Gallenkamp apparatus in open glass capillary tubes and
are uncorrected. Infrared spectra were recorded on a PerkineElmer
(Norwalk, CT) Spectrum One FT spectrophotometer and band po-
sitions are given in reciprocal centimeters (cm1). 1H NMR and 13C
NMR spectra were recorded on a Varian VX Mercury spectrometer
operating at 300 and 75 MHz for 1H and 13C, respectively, using
CDCl3 and DMSO-d6 as solvents. Chemical shifts are reported in
parts per million (ppm) relative to the residual non-deuterated
solvent resonance: CDCl3, d 7.26 (1H NMR) and d 77.3 (13C NMR);
DMSO-d6, d 2.48 (1H NMR) and d 40.1 (13C NMR). J values are given
in Hz. Gas chromatography (GC)/mass spectroscopy (MS) was
performed on a HewlettePackard 6890e5973 MSD at low resolu-
tion. Liquid chromatography (LC)/mass spectroscopy (MS) was
performed on a spectrometer Agilent 1100 series LC-MSD Trap
System VL. Elemental analyses were performed on a Eurovector
Euro EA 3000 analyzer. Chromatographic separations were
Fig. 4. Toxicity of 1o (left) and1n (right) for THP-1monocytes, as assessed bymeasuring LDH release (left axis) or trypan blue staining (right axis). Data aremean SD of 3 independent
determinations (when non visible, SD are smaller than the symbol). Statistical analysis: one-way ANOVAwith Dunnet’s post-hoc test vs control: *: p < 0.05; **: p < 0.01.
A. Catalano et al. / European Journal of Medicinal Chemistry 64 (2013) 357e364 361performed on silica gel columns by column chromatography on
silica gel (Kieselgel 60, 0.040e0.063 mm, Merck, Darmstadt, Ger-
many) as described elsewhere [29e31]. TLC analyses were per-
formed on precoated silica gel on aluminum sheets (Kieselgel 60
F254, Merck).4.2. General procedure for the synthesis of 4-substituted
nitrobenzene derivatives (3eeh,n) and 4-(phenoxymethyl)aniline
(6i)
The method adopted for the synthesis of 1-benzyloxy-4-
nitrobenzene (3e) is described. A solution of diisopropyl azodi-
carboxylate (DIAD, 5.60 g, 27.8 mmol) in dry THF (60 mL) was
added dropwise to a solution of benzyl alcohol (2e) (2.0 g,
18.5 mmol), 4-nitrophenol (3.86 g, 27.8 mmol), and triphenyl-
phosphine (7.28 g, 27.8 mmol) in dry THF (100 mL) under N2 at-
mosphere at room temperature. The reaction mixture was stirred
overnight and then concentrated in vacuo. Et2O was added to the
residue and the solid filtered off. The filtrate was evaporated and
the residue was purified by column chromatography on silica gel
(EtOAc/petroleum ether 1:9) to give a white solid which was
recrystallized from EtOAc/petroleum ether to give 3.33 g (79%) of
white crystals: mp 107e108 C; IR (KBr): 1509, 1347 (NO2) cm1;
GC/MS (70 eV) m/z (%) 229 (Mþ, 3), 91 (100). Other spectroscopic
data were in agreement with the literature [32].
4.2.1. 1-Nitro-4-(2-phenylethoxy)benzene (3f)
Prepared as reported above for 3e starting from 2f and 4-
nitrophenol. Yield: 72%; white solid: mp 59e60 C (EtOAc/petro-
leum ether); IR (KBr): 1510, 1338 (NO2) cm1; GC/MS (70 eV) m/z
(%) 243 (Mþ, 14), 105 (100). Other spectroscopic data were in
agreement with the literature [33].
4.2.2. 1-Nitro-4-(3-phenylpropoxy)benzene (3g)
Prepared as reported above for 3e starting from 2g and 4-
nitrophenol. Yield: 25%; slightly yellowish crystals: mp 82e83 C
(EtOAc/hexane); IR (KBr): 1514,1332 (NO2) cm1; GC/MS (70 eV)m/
z (%) 257 (Mþ, 49), 91 (100); 1H NMR (CDCl3): d 2.15 (quintet,
J ¼ 6.9 Hz, 2H, CH2CH2CH2), 2.83 (t, J ¼ 7.4 Hz, 2H, CH2eAr), 4.05 (t,
J ¼ 6.3 Hz, 2H, CH2eOAr), 6.93 (d, J ¼ 9.3 Hz, 2H, Ar), 7.15e7.35 (m,
5H, Ar), 8.19 (d, J ¼ 9.3 Hz, 2H, Ar); 13C NMR (CDCl3): d 30.7 (1C),
32.2 (1C), 67.9 (1C), 114.6 (2C), 126.1 (2C), 126.4 (1C), 128.7 (4C),
141.1 (1C), 142.0 (1C), 164.3 (1C).
4.2.3. 1-Nitro-4-(4-phenylbutoxy)benzene (3h)
Prepared as reported above for 3e starting from 2h and 4-
nitrophenol. Yield: 78%; white crystals: mp 54e55 C (EtOAc/pe-
troleum ether); IR (KBr): 1498,1331 (NO2) cm1; GC/MS (70 eV)m/z(%) 271 (Mþ, 13), 91 (100); 1H NMR (CDCl3): d 1.75e1.95 (m, 4H,
CH2CH2CH2CH2), 2.71 (t, J ¼ 6.9 Hz, 2H, CH2eAr), 4.06 (t, J ¼ 5.6 Hz,
2H, CH2eOAr), 6.92 (d, J¼ 9.1 Hz, 2H, Ar), 7.15e7.35 (m, 5H, Ar), 8.19
(d, J ¼ 9.1 Hz, 2H, Ar); 13C NMR (CDCl3): d 27.9 (1C), 28.8 (1C), 35.7
(1C), 68.9 (1C), 114.6 (2C), 126.1 (2C), 126.2 (1C), 128.6 (4C), 141.6
(1C), 142.1 (1C), 164.4 (1C).
4.2.4. Synthesis of 1-chloro-4-[(4-nitrophenoxy)methyl]benzene
(3n)
Prepared as reported above for 3e starting from 2n and 4-
nitrophenol. Yield: 47%; off-white crystals: mp 114e115 C
(EtOAc/petroleum ether); IR (KBr): 1505, 1337 (NO2) cm1; GC/MS
(70 eV)m/z (%) 263 (Mþ, 2), 125 (100); 1H NMR (CDCl3): d 5.13 (br s,
exch D2O, 2H, NH2), 7.02 (d, J ¼ 9.1 Hz, 2H, Ar), 7.32e7.44 (m, 4H,
Ar), 8.21 (d, J ¼ 9.3 Hz, 2H, Ar); 13C NMR (CDCl3): d 70.1 (1C), 115.1
(2C), 126.2 (2C), 129.0 (2C), 129.2 (2C), 134.2 (1C), 134.7 (1C), 142.1
(1C), 163.6 (1C).
4.2.5. 4-(Phenoxymethyl)aniline (6i)
Prepared as reported above for 3e starting from 5 and phenol.
Yield: 59%; gold crystals: mp 177e178 C (CHCl3/hexane); IR (KBr):
3398 (NH2) cm1; GC/MS (70 eV)m/z (%) 199 (Mþ, 3), 106 (100); 1H
NMR (CDCl3): d 3.70 (br s, exch D2O, 2H, NH2), 4.93 (s, 2H, CH2), 6.68
(d, J ¼ 8.8 Hz, 2H, Ar), 6.95e7.05 (m, 3H, Ar), 7.20e7.35 (m, 3H, Ar);
13C NMR (DMSO-d6): d 60.4 (1C), 112.8 (2C), 115.4 (2C), 123.8 (1C),
127.4 (1C), 128.8 (2C), 130.1 (2C), 148.4 (1C), 171.0 (1C).4.3. General procedure for the synthesis of 4-substituted anilines
(6feh) [34,35]
The method adopted for the synthesis of 4-(2-phenylethoxy)
aniline (6f) is described. A stirring suspension of 10% Pd/C (0.17 g) in
2-propanol (10 mL) and water (1 mL) was brought to reflux. Next,
nitro derivative 3f (0.40 g, 1.64 mmol) dissolved in THF (4 mL) and
solid ammonium formate (0.41 g, 6.58 mmol) were added. After
1.5 h the catalyst was removed by filtration and the solvent was
evaporated in vacuo to give a crude residue that was taken up with
EtOAc and washed with water. Then the solvent was removed in
vacuo giving 0.28 g (80%) of a dark brown oil: GC/MS (70 eV)m/z (%)
213 (Mþ, 100). Other spectroscopic data were in agreement with
the literature [24].
4.3.1. 4-(3-Phenylpropoxy)aniline (6g)
Prepared as reported above for 6f starting from 3g. Yield: 72%;
brown solid: mp 60e61 C; IR (KBr): 3403 (NH2) cm1; GC/MS
(70 eV) m/z (%) 227 (Mþ, 94), 109 (100); 1H NMR (CDCl3): d 2.06
(quintet, J¼ 7.0 Hz, 2H, CH2CH2CH2), 2.80 (t, J¼ 7.6 Hz, 2H, CH2eAr),
3.42 (br s, exch D2O, 2H, NH2), 3.89 (t, J¼ 6.3 Hz, 2H, CH2eOAr), 6.64
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Ar); 13C NMR (CDCl3): d 31.2 (1C), 32.4 (1C), 67.9 (1C), 116.0 (2C),
116.9 (2C), 126.1 (1C), 128.7 (4C), 139.8 (1C), 141.9 (1C), 152.6 (1C).
4.3.2. 4-(4-Phenylbutoxy)aniline (6h)
Prepared as reported above for 6f starting from 3h. Yield: 90%;
brown oil; IR (neat): 3361 (NH2) cm1; GC/MS (70 eV) m/z (%) 241
(Mþ, 53), 109 (100); 1H NMR (CDCl3): d 1.72e1.88 (m, 4H,
CH2CH2CH2CH2), 2.62e2.75 (m, 2H, CH2eAr), 3.12 (br s, 2H, NH2),
3.85e3.95 (m, 2H, CH2eOAr), 6.60e6.68 (m, 2H, Ar), 6.70e6.78 (m,
2H, Ar), 7.15e7.35 (m, 5H, Ar); 13C NMR (CDCl3): d 28.1 (1C), 29.3
(1C), 35.9 (1C), 68.7 (1C), 116.0 (2C), 116.7 (2C), 126.0 (1C), 128.5
(2C), 128.7 (2C), 140.0 (1C), 142.5 (1C), 152.6 (1C).
4.4. General procedure for the synthesis of 4-substituted anilines (5
and 6e,n)
The method adopted for the synthesis of 4-
aminophenylmethanol (5) is described. Catalytic hydrogenation of
4 (1.50 g, 9.8 mmol) in 30 mL of a mixture of MeOH and absolute
EtOH (2/1) was conducted at room temperature for 24 h in the
presence of 10% palladium on carbon at 10 bar. The catalyst was
removed by filtration and the residue taken up with EtOAc and
washedwith water. The solvent was removed to give 1.03 g (85%) of
a yellow solid which was recrystallized from EtOAc/petroleum
ether to give 0.65 g of yellowish crystals: mp 65e66 C; GC/MS
(70 eV) m/z (%) 123 (Mþ, 100). Other spectroscopic data were in
agreement with the literature [36].
4.4.1. 4-Benzyloxyaniline (6e)
Prepared as reported above for 5 starting from 3e. Yield: 90%;
dark green solid: mp 68e69 C; IR (KBr): 3355 (NH2) cm1; GC/MS
(70 eV) m/z (%) 199 (Mþ, 19), 108 (100); LC/MS m/z (%): 200
(Mþ þ H). Other spectroscopic data were in agreement with the
literature [24].
4.4.2. Synthesis of 4-[(4-chlorobenzyl)oxy]aniline (6n)
Prepared as reported above for 5 starting from 3n. This reaction
was carried out at room temperature for 20 min in the presence of
10% palladium on carbon at 3 bar. Yield: 49%; brown crystals: mp
108e109 C (EtOAc/hexane); IR (KBr): 3366 (NH2) cm1; GC/MS
(70 eV) m/z (%) 233 (Mþ, 14), 108 (100); 1H NMR (CDCl3): d 3.44 (br
s, exch D2O, 2H, NH2), 4.95 (s, 2H, CH2), 6.58e6.67 (m, 2H, Ar),
6.75e6.85 (m, 2H, Ar), 7.34 (s, 4H, Ar).
4.5. General procedure for the synthesis of 6-substituted-2-amino-
1,3-benzothiazoles (1bei)
The synthesis of 6-ethoxy-1,3-benzothiazol-2-amine (1c), ob-
tained following a general procedure for the preparation of ami-
nobenzothiazoles described in the literature [13,14] is described.
Aniline 6c (1.0 g, 7.36 mmol) and NH4SCN (1.6 g, 21.9 mmol) were
dissolved in a 20% formic acideglacial acetic acid mixture
(100 mL) and cooled to 3 C with stirring, under N2. With the
exclusion of light from the reaction mixture, bromine (0.30 mL
dissolved in 20 mL of glacial acetic acid) was added dropwise,
while the reaction temperature was kept between 3 C and 0 C.
The light shield was removed and the mixture was allowed to
warm to room temperature overnight. Sodium hydroxide pellets
and ice were added with stirring until pH 11 was attained, and the
mixture was extracted with EtOAc. The organic layer was sepa-
rated and filtered through celite to remove polythiocyanogen
(SCN)n. The organic layer was then washed with water, saturated
NaHCO3 and brine; then, the solvent was evaporated in vacuo. The
residue was purified by flash chromatography (EtOAc/petroleumether 1:1) to give 0.93 g (65%) of an orange solid: mp 163e164 C;
IR (KBr): 3436 (NH2) cm1; GC/MS (70 eV) m/z (%) 194 (Mþ, 81),
165 (100); 1H NMR (DMSO-d6): d 1.28 (t, J ¼ 6.9 Hz, 3H, CH3), 3.34
(br s, exch D2O, 2H, NH2), 3.96 (quartet, J ¼ 7.0 Hz, 2H, CH2), 6.64e
6.80 (m, 1H, Ar), 7.16e7.28 (m, 2H, Ar); 13C NMR (DMSO-d6): d 15.5
(1C), 64.1 (1C), 106.8 (1C), 114.0 (1C), 118.7 (1C), 132.5 (1C), 147.4
(1C), 154.1 (1C), 165.4 (1C). Anal. calcd. for C9H10N2OS$0.17H2O
(197.25) %: C, 54.80; H 5.28; N 14.20. Found: C, 55.02; H 5.13; N
13.92.
4.5.1. 6-Methoxy-1,3-benzothiazol-2-amine (1b)
Prepared as reported above for 1c starting from 6b. Yield: 26%;
beige crystals: mp: 162e163 C (CHCl3/hexane); IR (KBr): 3388
(NH2) cm1; GC/MS (70 eV) m/z (%) 180 (Mþ, 81), 165 (100); 1H
NMR (DMSO-d6): d 3.32 (br s, exch D2O, 2H, NH2), 3.71 (s, 3H, CH3),
6.75e6.85 (m, 1H, Ar), 7.15e7.30 (m, 2H, Ar); 13C NMR (CDCl3):
d 56.1 (1C), 105.6 (1C), 113.9 (1C), 119.9 (1C), 132.9 (1C), 146.4 (1C),
155.9 (1C), 164.3 (1C). Anal. calcd. for C8H8N2OS$0.50H2O (189.24)
%: C, 50.78; H 4.79; N 14.80. Found: C, 50.82; H 4.21; N 14.43.
4.5.2. 6-Phenoxy-1,3-benzothiazol-2-amine (1d)
Prepared as reported above for 1c starting from 6d. Yield: 65%;
brown crystals: mp: 171e172 C (EtOAc/petroleum ether); GC/MS
(70 eV)m/z (%) 242 (Mþ, 100). Anal. calcd. for C13H10N2OS$0.20H2O
(245.90) %: C, 63.50; H 4.26; N 11.39. Found: C, 63.80; H 3.89; N
11.41. Other spectroscopic data were in agreement with the litera-
ture [13].
4.5.3. 6-(Benzyloxy)-1,3-benzothiazol-2-amine (1e)
Prepared as reported above for 1c starting from 6e. Yield: 20%;
brown crystals: mp: 152e153 C (EtOAc/petroleum ether); IR (KBr):
3436 (NH2) cm1; GC/MS (70 eV)m/z (%) 256 (Mþ, 15),165 (100); 1H
NMR (CDCl3): d 5.09 (s, 2H, CH2), 5.21 (br s, exch D2O, 2H, NH2), 6.98
(dd, J ¼ 8.8, 2.5 Hz, 1H, Ar benzothiazole), 7.20 (d, J ¼ 2.5 Hz, 1H, Ar
benzothiazole), 7.28e7.48 (m, 6H, Ar); 13C NMR (CDCl3): d 71.1 (1C),
106.9 (1C), 114.8 (1C), 120.0 (1C), 127.7 (2C), 128.2 (1C), 128.8 (2C),
132.9 (1C), 137.2 (1C), 146.6 (1C), 155.1 (1C), 164.2 (1C). Anal. calcd.
for C14H12N2OS$0.33H2O (262.32) %: C, 64.10; H 4.87; N 10.68.
Found: C, 64.27; H 4.75; N 10.32.
4.5.4. 6-(2-Phenylethoxy)-1,3-benzothiazol-2-amine (1f)
Prepared as reported above for 1c starting from 6f. Prepared as
reported above for 1c starting from 6f. Yield: 59%; brown crystals:
mp 116e117 C (EtOAc/hexane); IR (KBr): 3432 (NH2) cm1; GC/MS
(70 eV)m/z (%) 270 (Mþ, 100); 1H NMR (CDCl3): d 3.10 (t, J ¼ 7.1 Hz,
2H, CH2eAr), 4.18 (t, J ¼ 7.0 Hz, 2H, CH2eOAr), 5.19 (br s, exch D2O,
2H, NH2), 6.90 (dd, J¼ 8.8, 2.5 Hz, 1H, Ar), 7.12 (d, J¼ 2.5 Hz, 1H, Ar),
7.20e7.37 (m, 5H, Ar), 7.43 (d, J ¼ 8.8 Hz, 1H, Ar); 13C NMR (CDCl3):
d 36.1 (1C), 69.8 (1C), 106.6 (1C), 114.6 (1C), 119.9 (1C), 126.7 (1C),
128.7 (2C), 129.2 (2C), 132.8 (1C), 138.4 (1C), 146.3 (1C), 155.1 (1C),
164.2 (1C). Anal. calcd. for C15H14N2OS (270.35) %: C, 66.64; H 5.22;
N 10.36. Found: C, 66.27; H 5.22; N 10.26.
4.5.5. 6-(3-Phenylpropoxy)-1,3-benzothiazol-2-amine (1g)
Prepared as reported above for 1c starting from 6g. Yield: 41%;
gold crystals: mp 126e127 C (EtOAc/hexane); IR (KBr): 3419
(NH2) cm1; GC/MS (70 eV) m/z (%) 284 (Mþ, 81), 166 (100); 1H
NMR (CDCl3): d 2.05e2.20 (m, 2H, CH2CH2CH2), 2.82 (t, J ¼ 7.6 Hz,
2H, CH2eAr), 3.96 (t, J ¼ 6.3 Hz, 2H, CH2eOAr), 5.18 (br s, exch D2O,
2H, NH2), 6.91 (dd, J¼ 8.5, 2.6 Hz, 1H, Ar), 7.11 (d, J¼ 2.5 Hz, 1H, Ar),
7.15e7.35 (m, 5H, Ar), 7.44 (d, J ¼ 8.5 Hz, 1H, Ar); 13C NMR (CDCl3):
d 31.1 (1C), 32.4 (1C), 67.9 (1C), 106.4 (1C), 114.6 (1C), 119.9 (1C),
126.2 (1C), 128.8 (4C), 132.8 (1C), 141.7 (1C), 146.3 (1C), 155.3 (1C),
164.1 (1C). Anal. calcd. for C16H16N2OS (284.38) %: C, 67.58; H 5.67;
N 9.85. Found: C, 67.52; H 5.60; N 9.81.
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Prepared as reported above for 1c starting from 6h. Yield: 62%;
beige solid: mp 98e99 C; IR (KBr): 3428 (NH2) cm1; GC/MS
(70 eV) m/z (%) 298 (Mþ, 28), 166 (100); 1H NMR (CDCl3): d 1.70e
1.90 (m, 4H, CH2CH2CH2CH2), 2.65e2.75 (m, 2H, CH2eAr), 3.90e
4.05 (m, 2H, CH2eOAr), 5.13 (br s, exch D2O, 2H, NH2), 6.89 (dd,
J ¼ 8.8, 2.5 Hz, 1H, Ar), 7.11 (d, J ¼ 2.5 Hz, 1H, Ar), 7.14e7.34 (m, 5H,
Ar), 7.43 (d, J ¼ 8.8 Hz, 1H, Ar); 13C NMR (CDCl3): d 28.1 (1C), 29.1
(1C), 35.8 (1C), 68.7 (1C), 106.3 (1C), 114.5 (1C), 119.9 (1C), 126.0
(1C), 128.6 (2C), 128.7 (2C), 132.9 (1C), 142.4 (1C), 146.3 (1C), 155.3
(1C), 164.1 (1C). Anal. calcd. for C17H18N2OS$0.2H2O (302.00) %: C,
67.61; H 6.14; N 9.28. Found: C, 67.84; H 6.02; N 9.22.
4.5.7. 6-(Phenoxymethyl)-1,3-benzothiazol-2-amine (1i)
Prepared as reported above for 1c starting from 6i. Yield: 46%;
yellow crystals: mp 168e169 C (EtOAc/petroleum ether); IR (KBr):
3393 (NH2) cm1; GC/MS (70 eV)m/z (%) 256 (Mþ, 1), 163 (100); 1H
NMR (CDCl3): d 5.10 (s, 2H, CH2), 5.27 (br s, exch D2O, 2H, NH2),
6.88e7.08 (m, 3H, Ar), 7.22e7.40 (m, 3H, Ar), 7.55 (d, J ¼ 8.3 Hz, 1H,
Ar), 7.69 (s, 1H, Ar); 13C NMR (CDCl3): d 70.2 (1C), 115.1 (2C), 119.5
(1C), 120.4 (1C), 121.2 (1C), 126.0 (1C), 129.7 (2C), 131.6 (1C), 132.3
(1C), 152.2 (1C), 159.0 (1C), 166.2 (1C). Anal. calcd. for
C14H12N2OS$0.5H2O (265.32) %: C, 63.37; H 4.94; N 10.56. Found: C,
63.11; H 4.66; N 10.49.
4.5.8. 6-[(4-Chlorobenzyl)oxy]-1,3-benzothiazol-2-amine (1n)
Prepared as reported above for 1c starting from 6n. Yield: 20%;
light pink crystals: mp 199e200 C (EtOAc/petroleum ether); IR
(KBr): 3439 (NH2) cm1; GC/MS (70 eV) m/z (%) 290 (Mþ, 18), 165
(100); 1H NMR (CDCl3): d 5.03 (s, 2H, CH2), 5.07 (br s, exch D2O, 2H,
NH2), 6.95 (dd, J¼ 8.8, 2.7 Hz,1H, Ar), 7.17 (d, J¼ 2.5 Hz,1H, Ar), 7.36
(s, 4H, Ar), 7.45 (d, J ¼ 8.8 Hz, 1H, Ar); 13C NMR (CDCl3): d 69.7 (1C),
107.5 (1C), 114.4 (1C), 118.7 (1C), 129.1 (2C), 130.1 (2C), 132.5 (1C),
133.0 (1C), 137.0 (1C), 147.8 (1C), 153.7 (1C), 165.6 (1C). Anal. calcd.
for C14H11ClN2OS (290.77) %: C, 57.83; H 3.81; N 9.63. Found: C,
58.16; H 3.77; N 9.70.
4.5.9. 6-(4-Chlorophenoxy)-1,3-benzothiazol-2-amine (1o)
Prepared as reported above for 1c starting from 6o. Yield: 87%;
slightly green powder: mp 168e169 C (CHCl3/hexane); IR (KBr):
3377 (NH2) cm1; GC/MS (70 eV) m/z (%) 276 (Mþ, 100); 1H NMR
(CDCl3): d 5.27 (br s, exch D2O, 2H, NH2), 6.91 (d, J ¼ 8.8 Hz, 2H, Ar),
7.0 (dd, J ¼ 8.5, 2.5 Hz, 1H, Ar), 7.15e7.35 (m, 3H, Ar), 7.50 (d,
J ¼ 8.5 Hz, 1H, Ar); 13C NMR (CDCl3): d 112.1 (1C), 118.5 (1C), 119.5
(2C), 120.0 (1C), 128.0 (1C), 129.9 (2C), 132.8 (1C), 148.8 (1C), 152.0
(1C), 157.1 (1C), 165.7 (1C). Anal. calcd. for C13H9ClN2OS (276.74) %:
C, 56.42; H 3.28; N 10.12. Found: C, 56.25; H 3.38; N 9.85.
4.6. Antibacterial studies
The in vitro minimum inhibitory concentrations (MICs, mg/mL)
were assessed by the broth microdilution method, using 96-well
plates, according toCLSI guidelines [15]. Stock solutions of the tested
compounds were obtained in DMSO. Stock solutions of lower con-
centrations were prepared for those substances which did not
dissolve well. Then two-fold serial dilutions in the suitable test
mediumbetween 512 and 0.5 mg/mLwere plated. To be sure that the
solvent had no adverse effect on bacterial growth, a control test was
carried out by using DMSO at its maximum concentration along
with the medium. Bacteria strains available as freeze-dried discs,
belonging to the ATCC collection, were used: Gram-positive strains
such as S. aureus 29213, E. faecalis 29212, and Gram-negative one
such as E. coli 25922. To preserve the purity of cultures and to allow
the reproducibility, a series of criovials of all microbial strains in
glycerolic mediumwere set up and stored at80 C. Pre-cultures ofeach bacterial strain were prepared in Cation Adjusted Muellere
Hinton broth (CAMHB) and incubated at 37 C until the growth
ceased. The turbidity of bacterial cell suspension was calibrated to
0.5 McFarland Standard by spectrophotometric method (625 nm,
range 0.08e0.10), and further the standardized suspension was
diluted 1:100withCAMHB tohave 1e2106 CFU/mL. Allwellswere
seeded with 100 mL of inoculum. A number of wells containing only
inoculated broth as control growth were prepared. The plates were
incubated at 37 C for 24 h, and theMIC values were recorded as the
last well containing no bacterial growth. TheMICswere determined
by using an antibacterial assay repeated twice in triplicate. Nor-
floxacin was used as reference drug.
4.7. Antifungal studies
Antifungal studies [16] were carried out against C. albicans
10231, C. parapsilosis 22019, C. tropicalis 750, C. krusei 6258,
belonging to the ATCC collection. Preparation of stock solutions and
purity of cultures preservation were obtained as above described
for antibacterial studies. Pre-cultures of each yeast strain were
prepared in Sabouraud broth 2% glucose (SAB), and incubated at
37 C until the growth ceased. The turbidity of yeast stock sus-
pension was calibrated to 0.5 McFarland Standard by spectropho-
tometric method (530 nm, range 0.12e0.15), and further the
standardized suspension was diluted first 1:50 with SAB and then
1:20 in the samemedium to have 1e5106 CFU/mL. All wells were
seeded with 100 mL of inoculum. A number of wells containing only
inoculated broth as control growth were prepared. The plates were
incubated at 37 C for 24e48 h, and the MIC values were recorded
as the last well containing no fungal growth. The MICs were
determined by using an antifungal assay repeated twice in tripli-
cates. Fluconazole was used as reference drug.
4.8. Molecular modeling studies
CLogP were calculated with ACD/ChemSketch v.12.01. Semi-rigid
dockings were carried out by means of AutoDock ver. 4.2 [37] on
the recently published homology models [26]. Blind dockings were
initially carried out to explore the accessibility of the target, and also
to prove the hypothesis of an inhibition of CA-CYP51 activity by the
coordination of the iron atom elicited by the benzothiazolemoiety of
the studies compounds. Calculating the affinity maps on the entire
protein surface the most favorable binding pose was, in all the in-
stances, exactly inside the active site lodge surrounding the heme
group. Afterward the cytochrome binding site was then defined as a
60 60 60 cubic box, 0.374A spaced, centered on the iron atom of
the heme group of CA-CYP51. Amber and AM1 charges were used for
protein and ligands respectively. For each compound 200 runs were
carried out, exploring the conformational space with the Lamarckian
Genetic Algorithm (LGA). To increase the docking performance the
population size and the number of energy evaluations were raised to
300 and 5,000,000 in that order, and for thewhole dockedmolecules
the best free energy of binding (FEB) poses were selected. To save
computational time, the lone high active compound 1ewas submit-
ted to flexible docking carried out exploring the side chainsflexibility
of the seven residues comprising the binding site proximity, namely
Tyr118, Leu121, Phe228, His310, Thr311, Leu376 andMet508. The 200
samplings carried in this way gave results similar to the previous 200
rigid runs, with a RMSD between the selected poses of 0.619.
4.9. Toxicity for eukaryotic cells
Toxicity was assessed toward THP-1 cells (ATCC TIB-202), a hu-
man myelomonocytic cell line displaying macrophage-like activity
[38]. These cellsweremaintained as a loose suspension in RPMI 1640
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glutamine/L in an atmosphere of 95% air/5% CO2. Cells were sub-
cultured every third day by gentle shaking, followed by pelleting and
reseeding at a density of 3  103 cells/mL. The cultures were used
after 2 days, when they reached a density of 0.1e5  106 cells/mL.
Cells were incubated with compounds at increasing concentrations
during 24 h and toxicity was evaluated using two assays in parallel,
namely the release of lactate dehydrogenase (LDH), a cytoplasmic
enzyme, and trypan blue exclusion assay [39]. This method repre-
sents a valid alternative to the MTT assay previously performed
[11,40]. LDH release was measured with the Roche LDH kit (cyto-
toxicity detection kit [LDH], Roche, Basel, Switzerland) in accordance
with themanufacturer’s instructions. Percentage of LDH release was
calculated relative to that of the control (cells incubated with 2%
DMSO; 0% LDH release), and that of cells lysed with Triton X-100
(100% LDH release). For trypan blue assay, 90 ml of cell suspension
incubated with compounds were mixed with 10 mL Trypan blue re-
agent (1:9 ratio) and incubated for 2e3 min at room temperature.
10 mL were transferred to a Burker counting chamber to determine
the number of viable (transparent) and non-viable (blue) cells. At
least 200 cellswere counted per condition. Percentagemortalitywas
determined as the ratio between the number of trypan blue labeled
cells and the total cell number.
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